Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E49.99 EPS (ttm)1.35 Insider Own0.10% Shs Outstand1.67B Perf Week1.52%
Market Cap112.49B Forward P/E29.38 EPS next Y2.30 Insider Trans-17.36% Shs Float1.67B Perf Month3.28%
Income2.25B PEG2.93 EPS next Q0.35 Inst Own72.90% Short Float1.40% Perf Quarter7.32%
Sales16.11B P/S6.98 EPS this Y-22.10% Inst Trans0.01% Short Ratio3.46 Perf Half Y15.62%
Book/sh9.35 P/B7.22 EPS next Y30.81% ROA6.70% Target Price70.33 Perf Year43.37%
Cash/sh4.56 P/C14.79 EPS next 5Y17.09% ROE14.80% 52W Range46.19 - 69.47 Perf YTD15.62%
Dividend1.48 P/FCF571.00 EPS past 5Y-5.90% ROI6.40% 52W High-2.74% Beta0.24
Dividend %2.19% Quick Ratio1.80 Sales past 5Y-3.30% Gross Margin77.20% 52W Low46.29% ATR1.20
Employees25000 Current Ratio1.90 Sales Q/Q6.00% Oper. Margin25.30% RSI (14)59.53 Volatility1.56% 1.50%
OptionableYes Debt/Eq0.48 EPS Q/Q26.80% Profit Margin14.00% Rel Volume0.71 Prev Close67.48
ShortableYes LT Debt/Eq0.46 EarningsJul 23 BMO Payout117.80% Avg Volume6.75M Price67.57
Recom2.30 SMA202.30% SMA502.22% SMA20011.79% Volume4,613,957 Change0.13%
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Jul-02-15 11:28AM  Biogen, AGTC Link Up To Develop Gene Therapy at Investor's Business Daily
Jun-30-15 04:02PM  Celgene bet $1 billion that this biotechs science can cure deadly cancers at Fortune
02:43PM  Why is Celgene So Darn Expensive? at Barrons.com
Jun-29-15 06:19PM  Your first trade for Tuesday, June 30 at CNBC
03:10PM  Alexandria Reveals 15-Year Anchor Lease with Bristol-Myers - Analyst Blog
10:24AM  Buy Sysco Foods, Bristol-Myers Now Before Their Dividend Payouts at TheStreet
Jun-26-15 05:05PM  Bristol-Myers Announces Job Cuts, Changes in R&D Sites - Analyst Blog
11:35AM  Is Big Pharma Advertising Getting Out of Control? at 24/7 Wall St.
11:20AM  Bristol-Myers Squibb's new R&D site will be about as big as Baxter's at bizjournals.com
08:30AM  Alexandria Real Estate Equities, Inc. Announces 15-Year Anchor Lease of 208,000 RSF with Bristol-Myers Squibb at 100 Binney Street at the Alexandria CenterĀ® at Kendall Square in Cambridge, MA PR Newswire
Jun-25-15 02:34PM  Bristol-Myers Squibb to open Cambridge R&D center at bizjournals.com
12:28PM  Bristol-Myers Squibb to shift research jobs
12:14PM  5 Huge Stocks to Trade for Huge Gains -- Must-See Charts at TheStreet
11:59AM  Bristol-Myers to Close Sites, Cut 100 Jobs at The Wall Street Journal
11:22AM  Bristol-Myers to close sites, cut 100 jobs at MarketWatch
11:08AM  Bristol-Myers to stop new antiviral drug research
11:06AM  Bristol-Myers Halts Virus-Drug Research, Cuts 100 Employees at Bloomberg
10:21AM  Lilly Blooms; Shares Up 4.5% on Patent Win, Merrill Upgrade at Barrons.com
09:30AM  Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation Business Wire
Jun-23-15 04:35PM  Portola, Bristol-Myers and Pfizer Report Encouraging Data - Analyst Blog
Jun-22-15 04:45PM  Bristol-Myers' (BMY) Melanoma Drug Opdivo Gets EU Nod - Analyst Blog
08:45AM  Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaba GlobeNewswire
02:00AM  Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University Business Wire
Jun-20-15 12:17AM  Merck's New Drugs Could Produce Big Profits at Barrons.com
Jun-19-15 04:05PM  Amgen Cancer Drug Vectibix Hits Phase III Primary Endpoint - Analyst Blog
02:20PM  Bulls keep piling into Bristol-Myers
11:37AM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients Business Wire
Jun-18-15 12:06PM  Healthy Leveraged Loans Issuance Volume Continues in June
09:00AM  Bristol-Myers Squibb to Announce Results for Second Quarter 2015 on July 23 Business Wire
Jun-17-15 02:32PM  How to Play the Fed Report; Bristol-Myers Downgrade Mocked at TheStreet
12:59PM  Halftime's Hottest Trades: BMY, SBUX, FDX & BOBE
12:21PM  Why Bristol-Myers Squibb Could Fall Nearly 10% at Barrons.com
12:17PM  Call of the day: Sell or buy Bristol-Myers?
10:39AM  Will Bristol-Myers Squibb (BMY) Stock React to Coverage Initiation? at TheStreet
06:28AM  Coverage initiated on Bristol-Myers by Piper Jaffray
Jun-16-15 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
Jun-15-15 04:30PM  Morgan Stanley's Positive Comments On Bristol-Myers Squibb
03:04PM  Moody's: Immuno-oncology drugs credit positive for drug makers; competition high at Moody's
Jun-12-15 11:23AM  Is Excitement Over Eli Lilly's Alzheimer's Drug Overdone? at Barrons.com
10:10AM  Stock Market News for June 12, 2015 - Market News
Jun-11-15 02:38AM  PeptiDream Announces Milestone in Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb Business Wire
12:00AM  Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing Research and Development Across Multiple Blood Cancers Through Immuno-Oncology Leadership at the 20th Congress of the European Hematology Association Business Wire
Jun-09-15 06:02PM  New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Prognosis Business Wire
Jun-07-15 11:56PM  Bristol-Myers Priced for a Miracle Cure at The Wall Street Journal
04:06PM  [$$] Bristol-Myers Priced for a Miracle Cure at The Wall Street Journal
Jun-05-15 02:00PM  Cancer treatment: Healing powers at Financial Times
Jun-04-15 12:15PM  Bristol-Myers call buying spikes
Jun-03-15 10:33PM  Vanda Pharmaceuticals, Inc.: Price momentum supported by strong fundamentals
08:17PM  Spotlight on Peregrine's Bavituximab Expansion at Investopedia
09:59AM  Amgen: The Quiet Winner at Barrons.com
09:12AM  Goldman Sachs: Your Mutual Fund Should Buy More of These 10 Stocks at Barrons.com
08:00AM  Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League Against Rheumatism (EULAR) 2015 Annual Meeting Business Wire
Jun-02-15 01:23PM  ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate at Forbes
01:08PM  Tests for new cancer drugs not reliable enough, doctors say
10:45AM  Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine Business Wire
10:00AM  Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference Business Wire
08:50AM  The 4 Overlooked Winners of ASCO at 24/7 Wall St.
Jun-01-15 05:44PM  Puma Biotech selloff is an overreaction: Analyst at CNBC
04:22PM  Bristol-Myers, Oncothyreon are big market movers
02:35PM  Bristol-Myers' Opdivo Superior to Standard-of-Care Therapies - Analyst Blog
02:17PM  Bristol-Myers Squibb: Recovering at Barrons.com
02:10PM  Puma Biotech is an opportunity: Pro
01:56PM  At ASCO: Bristol-Myers Rises on More Data About Cancer Drug at Barrons.com
01:55PM  Researcher makes job switch, gets sued by Bristol-Myers at bizjournals.com
01:08PM  Merck's fight against cancer
12:59PM  Top trades for the 2nd half: TXN, BMY & more
12:55PM  Bristol's CEO optimistic of Opdivo's results at CNBC
12:39PM  ImmunoGen, Bristol make strides in cancer battle at MarketWatch
11:39AM  Bristol-Myers Sues a Former Oncology Exec for Leaving for AstraZeneca at The Wall Street Journal
10:37AM  Stocks Step Out To Mixed Start; Bristol Myers Rises, Wynn Fades at Investor's Business Daily
10:18AM  A period of sustained growth: Bristol-Myers Squibb CEO
09:12AM  Intel buys Altera; Bristol-Meyers drug combo promising; Microsoft Windows 10 date
08:33AM  Bristol-Myers Slumps: BMY Falls 6.6% in Session - Tale of the Tape
08:21AM  Income jumps but spending flat; Microsoft's new OS; High priced drugs under scrutiny
07:44AM  U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma Business Wire
07:43AM  ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab at TheStreet
06:49AM  The Biggest Selling Cancer Drugs In 2020 Show Significant Change Expected In Five Short Years at Forbes
04:16AM  Soaring Cost, Toxic Effects Drive Race for Cancer Tests
01:34AM  High Drug Prices Attacked at Meeting at The Wall Street Journal
12:27AM  Pairing of Two Bristol-Myers Drugs Sees Success in Battling Skin Cancer, Study Says at The Wall Street Journal
12:27AM  High Prices for Drugs Attacked at Meeting at The Wall Street Journal
12:00AM  Soaring Cost, Toxic Effects Drive Race for Better Cancer Tests at Bloomberg
May-31-15 05:35PM  Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial Business Wire
02:35PM  Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma Business Wire
12:40PM  Celldex vaccine helps brain cancer patients live longer -study
08:13AM  Study: Pair of Bristol-Myers Drugs Sees Success in Battling Skin Cancer at The Wall Street Journal
07:44AM  Cancer drug combo boosts survival rate at Financial Times
07:30AM  Cancer Drug Combination Is Potent, in Response and Side Effects at Bloomberg
07:30AM  Bristol-Myers Squibb Has A Cancer Breakthrough. Here's Why It Should Cut The Price at Forbes
May-30-15 05:00AM  'Fast Money' Recap: Bristol-Myers' Stock Is Ailing, Health Care on the Rise at TheStreet
May-29-15 06:47PM  Trading pharma: 5 plays on Bristol's rough day at CNBC -6.58%
05:01PM  BMY hit on disappointing drug trial
05:00PM  Buying into biotech: 5 trades on 3 stocks
04:18PM  Bristol-Myers stock take an afternoon tumble on disappointing drug trial data at MarketWatch
04:07PM  Why Bristol-Myers Squibb is Down 7% Today at Barrons.com
02:58PM  At ASCO: Bristol, Merck Drugs Shrink Several Tumor Types at Barrons.com
02:57PM  Bristol-Myers sues immunotherapy exec who left for AstraZeneca
02:18PM  Doctors hail new front in fight against cancer at Financial Times
02:02PM  Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibbs PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma Business Wire
02:02PM  Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company's products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caldarella Joseph CSVP & ControllerJun 04Sale65.7116,9721,115,22959,284Jun 08 04:17 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,55409,047Apr 03 03:39 PM
Cuss Francis MEVP & CSOMar 16Option Exercise25.52114,0102,909,160380,699Mar 17 05:54 PM
Cuss Francis MEVP & CSOMar 16Sale67.81114,6667,775,501266,033Mar 17 05:54 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 16Sale67.087,000469,56022,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 13Sale66.6759139,40231,015Mar 16 07:01 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 13Sale66.795,000333,97229,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.002,068042,368Mar 12 06:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.005,287035,218Mar 12 06:54 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.003,271052,348Mar 12 06:54 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.008,0190269,160Mar 12 06:54 PM
Caforio GiovanniChief Operating OfficerMar 10Option Exercise0.0010,579071,322Mar 12 06:54 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.001,788050,485Mar 12 06:55 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.005,212058,799Mar 12 06:55 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.002,977076,835Mar 12 06:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0013,2390184,290Mar 12 06:55 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0048,8500411,731Mar 12 06:56 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.009,9970307,535Mar 12 06:53 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.004,54608,057Mar 12 06:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Sale65.8410,343680,94231,606Mar 12 06:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043059,141Mar 10 04:53 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931074,668Mar 10 04:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043040,624Mar 10 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400374,863Mar 10 04:51 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528030,053Mar 10 04:52 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724048,631Mar 10 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390054,339Mar 10 04:53 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0090261,937Mar 10 04:54 PM
Caforio GiovanniChief Operating OfficerMar 06Option Exercise0.002,889061,986Mar 10 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230171,251Mar 10 04:52 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 06Option Exercise0.005,5730298,970Mar 10 04:52 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Sale66.2410,468693,45249,031Mar 10 04:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.008,250060,609Mar 04 09:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.008,249043,860Mar 04 09:38 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 02Option Exercise0.0019,995034,176Mar 04 09:38 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 02Option Exercise0.0044,0840316,255Mar 04 09:39 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.0022,851070,125Mar 04 09:37 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.0023,8030270,105Mar 04 09:37 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.0018,907060,423Mar 04 09:37 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.005,725050,278Mar 04 09:37 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.0015,271079,730Mar 04 09:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.00231,2800643,964Mar 04 09:36 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.001,033044,363Mar 04 05:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 02Option Exercise0.009,7470108,016Mar 04 05:14 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.003,7030245,358Mar 04 05:14 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.003,182040,705Mar 04 05:14 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.001,360051,827Mar 04 05:12 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.002,475064,025Mar 04 05:13 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.001,174035,654Mar 04 05:13 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.001,494046,893Mar 04 05:13 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.0033,5310416,594Mar 04 05:13 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Option Exercise22.1427,938618,54759,838Feb 10 06:11 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Sale60.1521,4781,291,98838,360Feb 10 06:11 PM
CORNELIUS JAMES MDirectorJan 30Sale60.6050,0003,029,975119,464Feb 03 06:18 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Option Exercise25.45112,5002,863,125473,309Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Option Exercise26.252,50065,6252,500Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Sale60.892,500152,2270Feb 02 07:05 PM
Schmukler Louis SPres., Global Mfg. & SupplyJan 29Sale60.735,250318,85014,182Feb 02 07:05 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Sale61.1490,2465,518,001383,063Feb 02 07:05 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM